ENANTA PHARMACEUTICALS INC
No enriched coverage for $ENTA in the last 7 days.
No SEC Form 4 filings for $ENTA in the last 30 days.
The article, titled "Number of shareholders of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA," appears to be a stub or a section heading from a financial data platform like TradingView. It indicates a focus on the number of shareholders for the company, Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), within the Pharmaceuticals: Major segment.
Enanta Pharmaceuticals (ENTA) reported a Q2 loss of $0.45 per share, surpassing the Zacks Consensus Estimate of a $0.46 loss, but missed revenue estimates with $17.16 million against a forecast of $17.56 million. The company's stock has underperformed the S&P 500 year-to-date, and its near-term outlook is rated as a Zacks Rank #3 (Hold), suggesting it will perform in line with the market. Investors are advised to consider the broader industry outlook, which is currently in the bottom 42% of Zacks industries.
Enanta Pharmaceuticals presented its strategy at the Citizens Life Sciences Conference, outlining Phase 3 plans for its RSV drug zelicapavir, targeting high-risk adults. The company also highlighted its second RSV candidate, EDP-323, which showed rapid viral load reduction, and announced expansion of its oral immunology pipeline with several small-molecule programs for mast cell-driven diseases and atopic dermatitis. Enanta reported a strong cash position of $242 million, providing funding into fiscal 2029 for these initiatives.
